Katoh Norito
Department of Dermatology, Kyoto Prefectural University of Medicine Graduate School of Medical Science, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
J Dermatol. 2009 Jul;36(7):367-76. doi: 10.1111/j.1346-8138.2009.00662.x.
Atopic dermatitis is a chronically relapsing inflammatory skin disease with an increasing prevalence. The guidelines for the treatment of atopic dermatitis enable us to manage many patients with atopic dermatitis under a global consensus, which also contributes to improving their quality of life. However, there remain some patients with atopic dermatitis whose symptoms cannot be satisfactorily controlled using the therapeutic management recommended by the guidelines. Recent genetic, immunological and physiological insights into the pathomechanisms of atopic dermatitis are expected to overcome the limitations of the currently available treatment. Advances in pharmacology and biotechnology will also provide more efficient and safer medications. In this review, the limitations of the currently available therapies and the advantages and disadvantages of new approaches for the treatment of atopic dermatitis including topical and systemic immunosuppressants as well as biologics and anti-pruritic agents are discussed. Potential new cellular targets for the treatment of atopic dermatitis are also illustrated.
特应性皮炎是一种患病率不断上升的慢性复发性炎症性皮肤病。特应性皮炎治疗指南使我们能够在全球共识下管理许多特应性皮炎患者,这也有助于改善他们的生活质量。然而,仍有一些特应性皮炎患者,其症状无法通过指南推荐的治疗管理得到满意控制。近期对特应性皮炎发病机制的遗传学、免疫学和生理学见解有望克服现有治疗方法的局限性。药理学和生物技术的进展也将提供更高效、更安全的药物。在本综述中,讨论了现有疗法的局限性以及治疗特应性皮炎新方法的优缺点,包括局部和全身免疫抑制剂以及生物制剂和止痒剂。还阐述了治疗特应性皮炎潜在的新细胞靶点。